We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-0.27%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.53B
AUM Growth
+$1.73M
Cap. Flow
-$160M
Cap. Flow %
-10.45%
Top 10 Hldgs %
69.53%
Holding
250
New
32
Increased
47
Reduced
70
Closed
82

Top Buys

Rank Stock Value
1
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
+$13.5M
2
ARAV
Aravive, Inc. Common Stock
ARAV
+$11.9M
3
ESPR
Esperion Therapeutics
ESPR
+$4.02M
4
AIXC
AIxCrypto Holdings Inc
AIXC
+$2.59M
5
HURA
TuHURA Biosciences
HURA
+$2.3M

Top Sells

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$59.2M
2
UTHR icon
United Therapeutics
UTHR
+$6.78M
3
TSRO
TESARO, Inc.
TSRO
+$5.95M
4
KITE
Kite Pharma, Inc.
KITE
+$4.37M
5
SPNC
Spectranetics Corp
SPNC
+$3.48M

Sector Composition

Rank Sector Weight
1 Healthcare 7.34%
2 Technology 0.16%
3 Materials 0.11%
4 Consumer Staples 0.04%
5 Consumer Discretionary 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SLS icon
126
CALL
SELLAS Life Sciences
SLS
$1.96B
$215K 0.01%
4
– –
NURO
127
DELISTED
NeuroMetrix, Inc. Common Stock
NURO
$190K 0.01%
+1,170
New +$193K
ADXS
128
PUT
DELISTED
Advaxis Inc
ADXS
$173K 0.01%
28
– –
ROKA
129
DELISTED
Sorrento Tech, Inc. Common Stock
ROKA
$173K 0.01%
237,322
-120,876
-34% -$219K
ADXS
130
DELISTED
Advaxis Inc
ADXS
$157K 0.01%
2,509
+1,127
+82% +$104K
ARAV
131
CALL
DELISTED
Aravive, Inc. Common Stock
ARAV
$155K 0.01%
105
+71
+209% +$7.16K
ROSG
132
DELISTED
Rosetta Genomics Ltd.
ROSG
$149K 0.01%
+141,741
New +$251K
GEVO icon
133
Gevo
GEVO
$353M
$140K 0.01%
11,241
-17,025
-60% -$210K
SCNI
134
Scinai Immunotherapeutics
SCNI
$1.34M
$139K 0.01%
+194
New +$159K
ARMP icon
135
Armata Pharmaceuticals
ARMP
$179M
$136K 0.01%
10,661
-41,583
-80% -$532K
NTRP icon
136
NextTrip
NTRP
$24.5M
$132K 0.01%
350
-165
-32% -$69.1K
CFRX
137
DELISTED
ContraFect Corporation
CFRX
$132K 0.01%
+149
New +$141K
SGLBW
138
DELISTED
Sigma Labs, Inc. Warrant
SGLBW
$131K 0.01%
246,519
-1,240
-0.5% -$1.02K
LUMO
139
PUT
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$124K 0.01%
14
-136
-91% -$10.4K
ADXS
140
CALL
DELISTED
Advaxis Inc
ADXS
$113K 0.01%
18
– –
ORKA
141
Oruka Therapeutics
ORKA
$5.28B
$110K 0.01%
+463
New +$165K
NBSE
142
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
$110K 0.01%
380
-1,323
-78% -$361K
IMNN icon
143
Imunon
IMNN
$6.47M
$101K 0.01%
345
-211
-38% -$65K
ACGN
144
CALL
DELISTED
Aceragen Inc
ACGN
$93K 0.01%
+3
New +$784
RNVA
145
DELISTED
Rennova Health, Inc.
RNVA
$91K 0.01%
31,125
+17,868
+135% +$76.4K
OTIC
146
CALL
DELISTED
Otonomy, Inc.
OTIC
$89K 0.01%
275
-504
-65% -$6.79K
ANTH
147
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$75K ﹤0.01%
52,046
-540,626
-91% -$768K
ATRS
148
PUT
DELISTED
Antares Pharma, Inc.
ATRS
$74K ﹤0.01%
+227
New +$700
GALT icon
149
PUT
Galectin Therapeutics
GALT
$230M
$72K ﹤0.01%
337
-304
-47% -$602
KPRX icon
150
Kiora Pharmaceuticals
KPRX
$11.3M
$54K ﹤0.01%
9
-55
-86% -$350K
4 5
6
7 8

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q3 2017 Portfolio in Review

As of Q3 2017, Sabby Management held 250 positions worth $1.53B, up 0.11% from $1.53B the previous quarter. Its ten largest holdings account for 70% of the portfolio.

Sabby Management withdrew a net $160M in Q3 2017, closing 82 positions and reducing 70 holdings. Its most notable exit was United Therapeutics, an estimated $6.78M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 7.3% of assets, down from 13% a quarter earlier, followed by Technology and Materials.

Against the trend, Sabby Management opened a new position in Sio Gene Therapies Inc. Common Stock worth $4.42M.

  • Sabby Management's largest Q3 2017 buy was Sio Gene Therapies Inc. Common Stock: 80,320 shares worth $4.42M.
  • Sabby Management added most to TuHURA Biosciences in Q3 2017, an estimated $2.3M increase.
  • Sabby Management's biggest Q3 2017 reduction was Bristol-Myers Squibb, cutting an estimated $59.2M.
  • Sabby Management fully exited United Therapeutics in Q3 2017, selling an estimated $6.78M.
  • Sabby Management's ten largest holdings make up 70% of its $1.53B portfolio in Q3 2017.
  • Sabby Management opened 32 new positions and closed 82 in Q3 2017.
  • Sabby Management's portfolio value rose 0.11% quarter-over-quarter to $1.53B.

Based on Sabby Management's 13F filing for Q3 2017, filed 14 Nov 2017.